Alteogen
Alteogen Inc. is a South Korean biotechnology company focused on developing long-acting biobetters, biosimilars, and antibody-drug conjugates. The company leverages proprietary technology platforms, notably Hybrozyme, which enables the subcutaneous administration of intravenously delivered biopharmaceuticals. Its core product pipeline centers on human hyaluronidase enzymes alongside biosimilar formulations targeting oncology and ophthalmic conditions. Primary revenue drivers are upfront technology licensing fees, development milestone payments, and ongoing royalty streams from global pharmaceutical licensees. Alteogen holds a prominent market position as a leading innovator in drug delivery formulation technologies. The company is headquartered in Daejeon, South Korea, and its shares trade on the KOSDAQ market.
16 of the funds FundTelligence covers report a position in Alteogen.
- Legal name
- Alteogen Inc
- Sector
- Health Care
- Country
- South Korea
- Funds holding it
- 16
Funds holding Alteogen
- Mercer Passive Emerging Markets Equity Fund — Mercer · 0.12 % (full portfolio disclosed, December 2025)
- Storebrand Emerging Markets Plus — Storebrand · 0.11 % (full portfolio disclosed, October 2026)
- Danske Invest Global Emerging Markets Index Restricted — Danske Invest · 0.1 % (full portfolio disclosed, July 2026)
- KLP AksjeFremvoksende Markeder Indeks — KLP · 0.09 % (full portfolio disclosed, June 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.09 % (full portfolio disclosed, September 2026)
- DNB Emerging Markets Index — DNB · 0.08 % (full portfolio disclosed, September 2026)
- Storebrand Emerging Markets — Storebrand · 0.08 % (full portfolio disclosed, October 2026)
- Storebrand Indeks Nye Markeder — Storebrand · 0.07 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 16 funds holding it.